drugset
drugset / Trial / NCT06800313

Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

NCT06800313 ↗

Phase 1/2 Recruiting 190 enrolled Janssen Research & Development, LLC
Non-randomizedSequentialOpen-labelTreatment

Summary

Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.

Timeline

Start
2025-02-06
Primary completion
2028-08-17
Completion
2028-08-17

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-101556143 Other / unclassified — Oral

Indications

metastatic prostate carcinoma